capabilitiesIn brief · · · Written with AI
OpenAI buys Orchestra Bio to build agents that coordinate drug development
The company says it will fold the platform into Rosalind, its models for life-sciences research. It gives no price or terms.
On 15 October, OpenAI announced that it has acquired Orchestra Bio, a platform biopharma teams use to coordinate drug development. Its team and technology will join Rosalind, OpenAI's set of models and tools for life-sciences research.
The company says the aim is agents that monitor studies and campaigns, work out which activities and timelines a problem in one part of a programme affects, and compare possible responses. Decisions would stay with scientists and programme leaders. OpenAI mentions Novo Nordisk, with which it says it has a partnership, and Moderna.
This is the company's own announcement, with no independent information. The text gives no price or terms for the deal.
Sources
Written by AI from these sources.
- OpenAI acquires Orchestra BioAccessed 21 October 2026